Valuation : Entrada Therapeutics, Inc.

Market Cap 257M 221M 208M 190M 356M 24.27B 357M 2.46B 954M 12.45B 965M 944M 40.12B P/E 2026 *
-1.79x
P/E 2027 * -1.99x
Enterprise Value 227M 195M 184M 168M 314M 21.43B 315M 2.17B 843M 10.99B 852M 834M 35.42B EV / Sales 2026 *
16.3x
EV / Sales 2027 * -0.96x
Free-Float
85.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week+1.86%
Current month+1.13%
1 month+0.99%
3 months+11.93%
6 months-38.64%
Current year-30.64%
1 week 6.76
Extreme 6.76
7.42
1 month 6.75
Extreme 6.75
7.79
Current year 5.63
Extreme 5.63
16.45
1 year 5.02
Extreme 5.02
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 45 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
3/9/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
2/9/26 Tax

Chief Executive Officer

-8,724 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%+1.86%+34.78%-49.58% 257M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.30%+0.42%+41.91%+154.87% 27.94B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.18%

Financials

2026 *2027 *
Net sales 13.89M 11.96M 11.25M 10.28M 19.22M 1.31B 19.27M 133M 51.58M 673M 52.17M 51.03M 2.17B 22.86M 19.67M 18.51M 16.91M 31.63M 2.16B 31.71M 219M 84.86M 1.11B 85.84M 83.97M 3.57B
Net income -173M -149M -140M -128M -240M -16.37B -240M -1.66B -644M -8.4B -651M -637M -27.05B -182M -157M -148M -135M -252M -17.22B -253M -1.74B -677M -8.83B -685M -670M -28.46B
Net Debt -30.12M -25.92M -24.39M -22.28M -41.68M -2.84B -41.79M -288M -112M -1.46B -113M -111M -4.7B -279M -240M -226M -206M -386M -26.35B -387M -2.67B -1.04B -13.52B -1.05B -1.03B -43.55B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
04/09/26 USD 7.130 -0.56% 341,729
03/09/26 USD 7.170 -1.78% 395,559
02/09/26 USD 7.300 +3.25% 306,542
01/09/26 USD 7.070 +0.28% 205,483
31/08/26 USD 7.050 +0.71% 450,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.130USD
Average target price
19.00USD
Spread / Average Target
+166.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock